Our Patents & Intellectual Property
Verb Biotics is building a robust intellectual property portfolio at the intersection of microbiome science and biotechnology. Our patented technologies span metabolic health, lipid support, renal and muscle health, the gut-brain axis, novel microbial strains, and microbiome detection technologies.
Explore our granted patent portfolio by technology area below.
Metabolic Health
Microbiome technologies for metabolic and cardiometabolic health
View Granted Patents
Patent Family
Specific bacteria for use as medicines, in particular to combat overweight, obesity, cardiometabolic diseases and inflammatory bowel diseases
United States
US 10,681,932
US 11,044,933
US 12,127,576
Europe
EP 3 592 869
Lipid Support
Microbiome technology targeting lipid and triglyceride health
View Granted Patents
Patent Family
Christensenellaceae bacteria in the prevention and/or treatment of hypertriglyceridemia
France
FR 1 904 346
Renal Support
Christensenellaceae-based technology for renal health
View Granted Patents
Patent Family
Christensenellaceae bacteria and composition containing them for the prevention and/or treatment of renal failure
Europe
EP 3 989 988
Spain
ES 2 957 110
United Kingdom
EP 3 989 988
Muscle Support
Microbiome technology targeting pathological muscle wasting
View Granted Patents
Patent Family
Christensenellaceae bacterium and composition containing it for the prevention and/or treatment of pathological muscle wasting or a disease characterized by pathological muscle wasting
France
FR 1 906 843
Gut-Brain & Mood Support
Microbiome intellectual property supporting gut-brain innovation
View Granted Patents
Patent Family
Massiliomicrobiota bacteria and composition containing them for use as a medicament
France
FR 1 906 844
Microbiota & Neurodegenerative Health
Microbiome technology targeting pathways associated with 2-hydroxyglutarate excess
View Granted Patents
Patent Family
Bacteria of the intestinal microbiota and composition containing them for use in the prevention and/or treatment of diseases characterized by 2-hydroxyglutarate excess
France
FR 1 906 845
LX05 Strain Technology
Proprietary Christensenella strain intellectual property
View Granted Patents
Patent Family
Bacterial strain belonging to the Christensenella genus and compositions
France
FR 2 009 377
Christensenella minuta Detection
Technology for the detection of Christensenella minuta
View Granted Patents
Patent Family
Detection method and kit for Christensenella minuta
Europe
EP 4 259 825
LX30 Strain Technology
Proprietary Christensenella strain intellectual property
View Granted Patents
Patent Family
Bacterial strain belonging to the Christensenella genus and compositions
France
FR 2 109 727
Licensed Intellectual Property
In addition to our owned intellectual property portfolio, Verb Biotics has rights to patented technology developed by Cornell University related to Christensenellaceae and metabolic health.
Modulation of Fat Storage
Proprietary Christensenella strain intellectual property
View Granted Patents
Patent Family
Modulation of fat storage in a subject by altering population levels of Christensenellaceae in the gastrointestinal tract
Europe
EP 3 134 509
United States
US 10,206,958
US 10,925,905
Patent information is provided for informational purposes. Certain patents are owned by third parties and licensed to Verb Biotics. Additional patent applications may be pending in the United States and other jurisdictions.
Our solutions
Learn how our function-first bioactives deliver specific mechanisms of action for targeted health outcomes.
Let's talk
Find out how our biotics can be added into your food, beverage or dietary supplements to restore microbiome health for every body.